Drugs that contain Sitagliptin Phosphate
1. List of Januvia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) | |
|
US6699871
(Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(a day ago) | |
|
US7125873
(Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(a day ago) | |
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Feb 12, 2023 |
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic